Whether neoadjuvant therapy for triple sun breast cancer is good or not should be judged according to the pathological assessment after treatment, the specific treatment effect is related to the severity of the patient’s condition, and the effect can be seen gradually after 4 to 6 times of treatment in general. Neoadjuvant therapy is a kind of preoperative treatment, which mainly includes neoadjuvant chemotherapy, neoadjuvant targeted therapy and neoadjuvant endocrine therapy, etc. It can reduce the size of breast lumps, inhibit the metastasis of tumors, and improve the success rate of breast-conserving surgery. While triple positive breast cancer refers to the situation where estrogen receptor, progesterone receptor and epidermal growth factor receptor are positive, if the patient’s condition is not particularly serious and there is a certain degree of willingness to breast-conserving, then neoadjuvant therapy can be carried out before surgical treatment. Generally, neoadjuvant therapy requires 2 to 3 treatments before it produces an effect, which can be assessed by the results of post-treatment tests. However, not all triple positive breast cancer patients can undergo neoadjuvant therapy. For example, people with anemia, abnormal liver function, infection, fever and other complications are not suitable, and patients should strictly follow the doctor’s arrangement.